{
    "clinical_study": {
        "@rank": "114294", 
        "arm_group": [
            {
                "arm_group_label": "Febuxostat", 
                "arm_group_type": "Experimental", 
                "description": "Days 1-7: febuxostat 40 mg qd. Days 8-14: RDEA3170 10 mg or placebo qd in combination with febuxostat 40 mg qd.\nDays 15-21: RDEA3170 10 mg or placebo qd."
            }, 
            {
                "arm_group_label": "RDEA3170", 
                "arm_group_type": "Experimental", 
                "description": "Days 1-7: RDEA3170 10 mg or placebo qd. Days 8-14: RDEA3170 10 mg or placebo qd in combination with febuxostat 40 mg qd.\nDays 15-21: febuxostat 40 mg qd."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the potential pharmacokinetic (PK) and pharmacodynamic (PD)\n      interaction between the XO inhibitor febuxostat and the investigational URAT1 inhibitor\n      RDEA3170 and provide information for potential future clinical studies using this\n      combination. Combination treatment using 2 drugs with different mechanisms of action may\n      achieve improved response and may allow the use of lower doses, resulting in fewer side\n      effects than the use of either drug alone."
        }, 
        "brief_title": "RDEA3170 and Febuxostat Drug Interaction Study", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  body weight \u2265 50 kg (110 lbs.) and a body mass index \u2265 18 and \u2264 40 kg/m2.\n\n          -  no clinically relevant abnormalities in vital signs, ECG, physical examination or\n             safety laboratory values, per the Investigator's judgment.\n\n          -  a screening serum urate level \u2265 4.5 mg/dL.\n\n        Exclusion Criteria:\n\n          -  history or suspicion of kidney stones.\n\n          -  history of cardiac abnormalities as assessed during screening, including abnormal and\n             clinically relevant electrocardiogram changes and/or family history of sudden death\n             in otherwise healthy individual between the ages of 1 and 30 years.\n\n          -  undergone major surgery within 3 months prior to Day 1.\n\n          -  donated blood or experienced significant blood loss (> 450 mL) within 12 weeks prior\n             to Day 1 or gave a plasma donation within 4 weeks prior to the Screening Period.\n\n          -  inadequate venous access or unsuitable veins for repeated venipuncture."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01883167", 
            "org_study_id": "RDEA3170-105"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Febuxostat", 
                    "RDEA3170"
                ], 
                "description": "RDEA3170 10 mg once daily (qd)", 
                "intervention_name": "RDEA3170 10 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Febuxostat", 
                    "RDEA3170"
                ], 
                "description": "Febuxostat 40 mg qd", 
                "intervention_name": "Febuxostat 40 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Febuxostat", 
                    "RDEA3170"
                ], 
                "description": "placebo qd", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Febuxostat"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kalamazoo", 
                    "country": "United States", 
                    "state": "Michigan", 
                    "zip": "49007"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1 Study to Evaluate the Potential Pharmacokinetic and Pharmacodynamic Interactions Between RDEA3170 and Febuxostat in Healthy Adult Male Subjects", 
        "overall_official": {
            "affiliation": "Ardea Biosciences, Inc.", 
            "last_name": "S. Baumgartner", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Profile from plasma and urine in terms of AUC, Tmax, Cmax, t1/2, Ae, and CLr\nAUC: area under the concentration-time curve; Tmax: time to maximum plasma concentration; Cmax: maximum plasma drug concentration; t1/2: apparent terminal half-life; Ae: amount excreted of unchanged drug into urine; CLr: renal clearance", 
            "measure": "PK profile of RDEA3170 from plasma and urine and febuxostat from plasma", 
            "safety_issue": "No", 
            "time_frame": "Days -1 (urine only), 7, 14, 21 and Days 8, 15, 22 (plasma only)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01883167"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Profile from serum and urine in terms of sUA concentration, renal clearance of uric acid, urine uric acid excretion amounts, and fractional excretion of uric acid.\nsUA: serum urate", 
                "measure": "PD profile of RDEA3170 and febuxostat alone and in combination", 
                "safety_issue": "No", 
                "time_frame": "Days -1, 7, 14, 21 and Days 8, 15, 22 (serum only)"
            }, 
            {
                "measure": "Incidence of Adverse Events and Changes in Laboratory, Electrocardiogram, and Vital Signs Parameters", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }
        ], 
        "source": "Ardea Biosciences, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ardea Biosciences, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}